Current Role at Stanford

Life Science Research Professional -1

Education & Certifications

  • BS, Istanbul Technical University, Molecular Biology and Genetics (2006)
  • MS, Istanbul Technical University, Molecular Bology and Genetics, Biotechnology (2008)


  • An oncogene-induced metabolic gene signature predicts poor outcome in breast cancer, Stanford University


    Palo Alto, California


All Publications

  • Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies. Molecular cancer therapeutics Rice, M. A., Hsu, E. C., Aslan, M., Ghoochani, A., Su, A., Stoyanova, T. 2019


    Prostate cancer remains among the leading causes of cancer-related deaths in men. Patients with aggressive disease typically undergo hormone-deprivation therapy. While treatment is initially very successful, these men commonly progress to lethal, castration resistant prostate cancer in 2-3 years. Standard therapies for castration resistant prostate cancer include second-generation anti-androgens, which prolong patient lifespan by only several months. It is imperative to advance our understanding of the mechanisms leading to resistance to identify new therapies for aggressive prostate cancer. This study identifies Notch1 as a therapeutic target in prostate cancer. Loss of Notch1 in aggressive prostate cancer cells decreases proliferation, invasion and tumorsphere formation. Therapeutic inhibition of Notch1 activity with gamma secretase inhibitors RO4929097 or DAPT in prostate cancer cells further results in decreased proliferative abilities. Loss of Notch1 and treatment of immunocompromised mice bearing prostate cancer xenografts with RO4929097 display significantly impaired tumor growth. Loss of Notch1 additionally decreased metastatic potential of prostate cancer cells in invasion assays in vitro as well as in vivo experiments. Moreover, treatment with gamma secretase inhibitors, or Notch1 gene deletion synergized with anti-androgen therapies, Enzalutamide or Abiraterone, to decrease the growth of prostate cancer cells. Combination of gamma secretase inhibitors with Abiraterone significantly inhibited cell migration and invasion, while combination with Enzalutamide reversed Enzalutamide induced migration and invasion. These collective findings suggest loss of Notch1 delays growth of CRPC, inhibits metastasis, and inhibition of Notch1 activation in conjunction with second-generation anti-androgen therapies could delay growth and progression of prostate cancer.

    View details for PubMedID 31028097

Footer Links:

Stanford Medicine Resources: